Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach
| Autor: | Florena M, Antonio Testa, Mario Adelfio Latteri, G. Bajardi, G. Mastrandrea, G. Curto, Nicolo' Gebbia, Calogero Cipolla, Vittorio Gebbia, Pischedda G, Roberto Valenza, G Cannata |
|---|---|
| Přispěvatelé: | Gebbia, V, Testa, A, Valenza, R, Latteri, MA, Bajardi, G, Mastrandrea, G, Cipolla, C, Pischedda, G, Curto, G, Cannata, G, Gebbia, N, Florena, M |
| Předmět: |
Adult
Male medicine.medical_specialty Mitomycin medicine.medical_treatment Adenocarcinoma Gastric Adenocarcinoma Chemotherapy Epidoxorubicin Mitomicin C Gastroenterology Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Neoplasm Metastasis Aged Epirubicin Aged 80 and over Pharmacology Chemotherapy business.industry Stomach Palliative Care Mitomycin C Combination chemotherapy Middle Aged medicine.disease Confidence interval Surgery Infectious Diseases medicine.anatomical_structure Oncology Fluorouracil Female business Progressive disease medicine.drug |
| Zdroj: | Scopus-Elsevier |
| Popis: | Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i.v. on days 1, 29; mitomycin C 10 mg/m2 i.v. on day 1. This cycle was repeated every 8 weeks. Out of a total of 34 evaluable patients, 2 (5.8%) had a complete response and 7 (20.6%) had a partial response with an overall median duration of 40 weeks (range 20-128). The median survival of responding patients was not reached after a mean follow-up of 76 weeks, while that of patients with no change and progressive disease was reached at 36 and 13 weeks respectively. Treatment was generally well tolerated with hematological and gastrointestinal toxicities being the major side-effects. Despite the use of epidoxorubicin 75 mg/m2, the 26.4% (95% confidence limits 16-36%) objective response rate is not satisfactory. Evaluation of more aggressive protocols is strongly recommended within the limits of controlled trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|